Skip to main content
Top
Published in: EJNMMI Research 1/2020

Open Access 01-12-2020 | NSCLC | Original research

Asphericity of tumor FDG uptake in non-small cell lung cancer: reproducibility and implications for harmonization in multicenter studies

Authors: Julian M. M. Rogasch, Christian Furth, Stephanie Bluemel, Piotr Radojewski, Holger Amthauer, Frank Hofheinz

Published in: EJNMMI Research | Issue 1/2020

Login to get access

Abstract

Background

Asphericity (ASP) of the primary tumor’s metabolic tumor volume (MTV) in FDG-PET/CT is independently predictive for survival in patients with non-small cell lung cancer (NSCLC). However, comparability between PET systems may be limited. Therefore, reproducibility of ASP was evaluated at varying image reconstruction and acquisition times to assess feasibility of ASP assessment in multicenter studies.

Methods

This is a retrospective study of 50 patients with NSCLC (female 20; median age 69 years) undergoing pretherapeutic FDG-PET/CT (median 3.7 MBq/kg; 180 s/bed position). Reconstruction used OSEM with TOF4/16 (iterations 4; subsets 16; in-plane filter 2.0, 6.4 or 9.5 mm), TOF4/8 (4 it; 8 ss; filter 2.0/6.0/9.5 mm), PSF + TOF2/17 (2 it; 17 ss; filter 2.0/7.0/10.0 mm) or Bayesian-penalized likelihood (Q.Clear; beta, 600/1750/4000). Resulting reconstructed spatial resolution (FWHM) was determined from hot sphere inserts of a NEMA IEC phantom. Data with approx. 5-mm FWHM were retrospectively smoothed to achieve 7-mm FWHM. List mode data were rebinned for acquisition times of 120/90/60 s. Threshold-based delineation of primary tumor MTV was followed by evaluation of relative ASP/SUVmax/MTV differences between datasets and resulting proportions of discordantly classified cases.

Results

Reconstructed resolution for narrow/medium/wide in-plane filter (or low/medium/high beta) was approx. 5/7/9 mm FWHM. Comparing different pairs of reconstructed resolution between TOF4/8, PSF + TOF2/17, Q.Clear and the reference algorithm TOF4/16, ASP differences was lowest at FWHM of 7 versus 7 mm. Proportions of discordant cases (ASP > 19.5% vs. ≤ 19.5%) were also lowest at 7 mm (TOF4/8, 2%; PSF + TOF2/17, 4%; Q.Clear, 10%). Smoothing of 5-mm data to 7-mm FWHM significantly reduced discordant cases (TOF4/8, 38% reduced to 2%; PSF + TOF2/17, 12% to 4%; Q.Clear, 10% to 6%), resulting in proportions comparable to original 7-mm data. Shorter acquisition time only increased proportions of discordant cases at < 90 s.

Conclusions

ASP differences were mainly determined by reconstructed spatial resolution, and multicenter studies should aim at comparable FWHM (e.g., 7 mm; determined by in-plane filter width). This reduces discordant cases (high vs. low ASP) to an acceptable proportion for TOF and PSF + TOF of < 5% (Q.Clear: 10%). Data with better resolution (i.e., lower FWHM) could be retrospectively smoothed to the desired FWHM, resulting in a comparable number of discordant cases.
Appendix
Available only for authorised users
Literature
1.
go back to reference Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–21.CrossRefPubMed Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–21.CrossRefPubMed
2.
go back to reference Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–60.CrossRefPubMed Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–60.CrossRefPubMed
3.
go back to reference Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27.CrossRefPubMed Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27.CrossRefPubMed
4.
go back to reference Artal Cortes A, Calera Urquizu L, Hernando CJ. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res. 2015;4(2):191–7.PubMedPubMedCentral Artal Cortes A, Calera Urquizu L, Hernando CJ. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res. 2015;4(2):191–7.PubMedPubMedCentral
5.
go back to reference Sharpnack MF, Ranbaduge N, Srivastava A, Cerciello F, Codreanu SG, Liebler DC, et al. Proteogenomic analysis of surgically resected lung adenocarcinoma. J Thorac Oncol. 2018;13(10):1519–29.CrossRefPubMedPubMedCentral Sharpnack MF, Ranbaduge N, Srivastava A, Cerciello F, Codreanu SG, Liebler DC, et al. Proteogenomic analysis of surgically resected lung adenocarcinoma. J Thorac Oncol. 2018;13(10):1519–29.CrossRefPubMedPubMedCentral
6.
go back to reference Wang L, Dong T, Xin B, Xu C, Guo M, Zhang H, et al. Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer. Eur Radiol. 2019;29(6):2958–67.CrossRefPubMed Wang L, Dong T, Xin B, Xu C, Guo M, Zhang H, et al. Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer. Eur Radiol. 2019;29(6):2958–67.CrossRefPubMed
7.
go back to reference Desseroit MC, Visvikis D, Tixier F, Majdoub M, Perdrisot R, Guillevin R, et al. Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III. Eur J Nucl Med Mol Imaging. 2016;43(8):1477–85.CrossRefPubMedPubMedCentral Desseroit MC, Visvikis D, Tixier F, Majdoub M, Perdrisot R, Guillevin R, et al. Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III. Eur J Nucl Med Mol Imaging. 2016;43(8):1477–85.CrossRefPubMedPubMedCentral
8.
go back to reference Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS ONE. 2016;11(1):e0146195.CrossRefPubMedPubMedCentral Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS ONE. 2016;11(1):e0146195.CrossRefPubMedPubMedCentral
9.
go back to reference Paesmans M, Garcia C, Wong CY, Patz EF Jr, Komaki R, Eschmann S, et al. Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. Eur Respir J. 2015;46(6):1751–61.CrossRefPubMed Paesmans M, Garcia C, Wong CY, Patz EF Jr, Komaki R, Eschmann S, et al. Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. Eur Respir J. 2015;46(6):1751–61.CrossRefPubMed
10.
go back to reference Vanhove K, Mesotten L, Heylen M, Derwael R, Louis E, Adriaensens P, et al. Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer. Cancer Treat Res Commun. 2018;15:7–12.CrossRefPubMed Vanhove K, Mesotten L, Heylen M, Derwael R, Louis E, Adriaensens P, et al. Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer. Cancer Treat Res Commun. 2018;15:7–12.CrossRefPubMed
11.
go back to reference Park S, Ha S, Lee SH, Paeng JC, Keam B, Kim TM, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE. 2018;13(1):e0189766.CrossRefPubMedPubMedCentral Park S, Ha S, Lee SH, Paeng JC, Keam B, Kim TM, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE. 2018;13(1):e0189766.CrossRefPubMedPubMedCentral
12.
go back to reference Arshad MA, Thornton A, Lu H, Tam H, Wallitt K, Rodgers N, et al. Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2019;46(2):455–66.CrossRefPubMed Arshad MA, Thornton A, Lu H, Tam H, Wallitt K, Rodgers N, et al. Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2019;46(2):455–66.CrossRefPubMed
13.
go back to reference Apostolova I, Ego K, Steffen IG, Buchert R, Wertzel H, Achenbach HJ, et al. The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. Eur J Nucl Med Mol Imaging. 2016;43(13):2360–73.CrossRefPubMed Apostolova I, Ego K, Steffen IG, Buchert R, Wertzel H, Achenbach HJ, et al. The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. Eur J Nucl Med Mol Imaging. 2016;43(13):2360–73.CrossRefPubMed
14.
go back to reference Apostolova I, Rogasch J, Buchert R, Wertzel H, Achenbach HJ, Schreiber J, et al. Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. BMC Cancer. 2014;14:896.CrossRefPubMedPubMedCentral Apostolova I, Rogasch J, Buchert R, Wertzel H, Achenbach HJ, Schreiber J, et al. Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. BMC Cancer. 2014;14:896.CrossRefPubMedPubMedCentral
15.
go back to reference Rogasch JMM, Furth C, Chibolela C, Hofheinz F, Ochsenreither S, Ruckert JC, et al. Validation of independent prognostic value of asphericity of (18)F-fluorodeoxyglucose uptake in non-small-cell lung cancer patients undergoing treatment with curative intent. Clin Lung Cancer. 2019;21:264–72.CrossRefPubMed Rogasch JMM, Furth C, Chibolela C, Hofheinz F, Ochsenreither S, Ruckert JC, et al. Validation of independent prognostic value of asphericity of (18)F-fluorodeoxyglucose uptake in non-small-cell lung cancer patients undergoing treatment with curative intent. Clin Lung Cancer. 2019;21:264–72.CrossRefPubMed
16.
go back to reference Sharma A, Mohan A, Bhalla AS, Sharma MC, Vishnubhatla S, Das CJ, et al. Role of various metabolic parameters derived from baseline 18F-FDG PET/CT as prognostic markers in non-small cell lung cancer patients undergoing platinum-based chemotherapy. Clin Nucl Med. 2018;43(1):e8–17.CrossRefPubMed Sharma A, Mohan A, Bhalla AS, Sharma MC, Vishnubhatla S, Das CJ, et al. Role of various metabolic parameters derived from baseline 18F-FDG PET/CT as prognostic markers in non-small cell lung cancer patients undergoing platinum-based chemotherapy. Clin Nucl Med. 2018;43(1):e8–17.CrossRefPubMed
17.
go back to reference Ma W, Wang M, Li X, Huang H, Zhu Y, Song X, et al. Quantitative (18)F-FDG PET analysis in survival rate prediction of patients with non-small cell lung cancer. Oncol Lett. 2018;16(4):4129–36.PubMedPubMedCentral Ma W, Wang M, Li X, Huang H, Zhu Y, Song X, et al. Quantitative (18)F-FDG PET analysis in survival rate prediction of patients with non-small cell lung cancer. Oncol Lett. 2018;16(4):4129–36.PubMedPubMedCentral
18.
go back to reference Houdu B, Lasnon C, Licaj I, Thomas G, Do P, Guizard AV, et al. Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer. Eur J Nucl Med Mol Imaging. 2019;46(2):421–8.CrossRefPubMed Houdu B, Lasnon C, Licaj I, Thomas G, Do P, Guizard AV, et al. Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer. Eur J Nucl Med Mol Imaging. 2019;46(2):421–8.CrossRefPubMed
19.
go back to reference Lasnon C, Enilorac B, Popotte H, Aide N. Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs). EJNMMI Res. 2017;7(1):30.CrossRefPubMedPubMedCentral Lasnon C, Enilorac B, Popotte H, Aide N. Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs). EJNMMI Res. 2017;7(1):30.CrossRefPubMedPubMedCentral
20.
go back to reference Zhuang M, Garcia DV, Kramer GM, Frings V, Smit EF, Dierckx R, et al. Variability and repeatability of quantitative uptake metrics in (18)F-FDG PET/CT of non-small cell lung cancer: impact of segmentation method, uptake interval, and reconstruction protocol. J Nucl Med. 2019;60(5):600–7.CrossRefPubMed Zhuang M, Garcia DV, Kramer GM, Frings V, Smit EF, Dierckx R, et al. Variability and repeatability of quantitative uptake metrics in (18)F-FDG PET/CT of non-small cell lung cancer: impact of segmentation method, uptake interval, and reconstruction protocol. J Nucl Med. 2019;60(5):600–7.CrossRefPubMed
21.
go back to reference Akamatsu G, Mitsumoto K, Taniguchi T, Tsutsui Y, Baba S, Sasaki M. Influences of point-spread function and time-of-flight reconstructions on standardized uptake value of lymph node metastases in FDG-PET. Eur J Radiol. 2014;83(1):226–30.CrossRefPubMed Akamatsu G, Mitsumoto K, Taniguchi T, Tsutsui Y, Baba S, Sasaki M. Influences of point-spread function and time-of-flight reconstructions on standardized uptake value of lymph node metastases in FDG-PET. Eur J Radiol. 2014;83(1):226–30.CrossRefPubMed
22.
go back to reference Armstrong IS, Kelly MD, Williams HA, Matthews JC. Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies. EJNMMI Phys. 2014;1(1):99.CrossRefPubMedPubMedCentral Armstrong IS, Kelly MD, Williams HA, Matthews JC. Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies. EJNMMI Phys. 2014;1(1):99.CrossRefPubMedPubMedCentral
23.
go back to reference Fleckenstein J, Hellwig D, Kremp S, Grgic A, Groschel A, Kirsch CM, et al. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial. Int J Radiat Oncol Biol Phys. 2011;81(4):e283–9.CrossRefPubMed Fleckenstein J, Hellwig D, Kremp S, Grgic A, Groschel A, Kirsch CM, et al. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial. Int J Radiat Oncol Biol Phys. 2011;81(4):e283–9.CrossRefPubMed
24.
go back to reference Dewalle-Vignion AS, Yeni N, Petyt G, Verscheure L, Huglo D, Beron A, et al. Evaluation of PET volume segmentation methods: comparisons with expert manual delineations. Nucl Med Commun. 2012;33(1):34–42.CrossRefPubMed Dewalle-Vignion AS, Yeni N, Petyt G, Verscheure L, Huglo D, Beron A, et al. Evaluation of PET volume segmentation methods: comparisons with expert manual delineations. Nucl Med Commun. 2012;33(1):34–42.CrossRefPubMed
25.
go back to reference Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rube C, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med. 2005;46(8):1342–8.PubMed Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rube C, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med. 2005;46(8):1342–8.PubMed
26.
go back to reference Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328–38.CrossRefPubMed Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328–38.CrossRefPubMed
27.
go back to reference Vandendriessche D, Uribe J, Bertin H, De Geeter F. Performance characteristics of silicon photomultiplier based 15-cm AFOV TOF PET/CT. EJNMMI Phys. 2019;6(1):8.CrossRefPubMedPubMedCentral Vandendriessche D, Uribe J, Bertin H, De Geeter F. Performance characteristics of silicon photomultiplier based 15-cm AFOV TOF PET/CT. EJNMMI Phys. 2019;6(1):8.CrossRefPubMedPubMedCentral
28.
go back to reference Hofheinz F, Dittrich S, Potzsch C, Hoff J. Effects of cold sphere walls in PET phantom measurements on the volume reproducing threshold. Phys Med Biol. 2010;55(4):1099–113.CrossRefPubMed Hofheinz F, Dittrich S, Potzsch C, Hoff J. Effects of cold sphere walls in PET phantom measurements on the volume reproducing threshold. Phys Med Biol. 2010;55(4):1099–113.CrossRefPubMed
29.
go back to reference Hofheinz F, Langner J, Petr J, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. An automatic method for accurate volume delineation of heterogeneous tumors in PET. Med Phys. 2013;40(8):082503.CrossRefPubMed Hofheinz F, Langner J, Petr J, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. An automatic method for accurate volume delineation of heterogeneous tumors in PET. Med Phys. 2013;40(8):082503.CrossRefPubMed
30.
go back to reference Apostolova I, Steffen IG, Wedel F, Lougovski A, Marnitz S, Derlin T, et al. Asphericity of pretherapeutic tumour FDG uptake provides independent prognostic value in head-and-neck cancer. Eur Radiol. 2014;24(9):2077–87.CrossRefPubMed Apostolova I, Steffen IG, Wedel F, Lougovski A, Marnitz S, Derlin T, et al. Asphericity of pretherapeutic tumour FDG uptake provides independent prognostic value in head-and-neck cancer. Eur Radiol. 2014;24(9):2077–87.CrossRefPubMed
31.
go back to reference Wetz C, Apostolova I, Steffen IG, Hofheinz F, Furth C, Kupitz D, et al. Predictive value of asphericity in pretherapeutic [(111)In]DTPA-octreotide SPECT/CT for response to peptide receptor radionuclide therapy with [(177)Lu]DOTATATE. Mol Imag Biol. 2017;19(3):437–45.CrossRef Wetz C, Apostolova I, Steffen IG, Hofheinz F, Furth C, Kupitz D, et al. Predictive value of asphericity in pretherapeutic [(111)In]DTPA-octreotide SPECT/CT for response to peptide receptor radionuclide therapy with [(177)Lu]DOTATATE. Mol Imag Biol. 2017;19(3):437–45.CrossRef
32.
go back to reference Wetz C, Genseke P, Apostolova I, Furth C, Ghazzawi S, Rogasch JMM, et al. The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE. PLoS ONE. 2019;14(5):e0216781.CrossRefPubMedPubMedCentral Wetz C, Genseke P, Apostolova I, Furth C, Ghazzawi S, Rogasch JMM, et al. The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE. PLoS ONE. 2019;14(5):e0216781.CrossRefPubMedPubMedCentral
33.
go back to reference Rogasch JMM, Hundsdoerfer P, Hofheinz F, Wedel F, Schatka I, Amthauer H, et al. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin’s lymphoma. BMC Cancer. 2018;18(1):521.CrossRefPubMedPubMedCentral Rogasch JMM, Hundsdoerfer P, Hofheinz F, Wedel F, Schatka I, Amthauer H, et al. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin’s lymphoma. BMC Cancer. 2018;18(1):521.CrossRefPubMedPubMedCentral
34.
go back to reference Meißner S, Janssen JC, Prasad V, Brenner W, Diederichs G, Hamm B, et al. Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with (68)Ga-PSMA-HBED-CC PET-positive prostate cancer lesions. EJNMMI Res. 2017;7(1):85.CrossRefPubMedPubMedCentral Meißner S, Janssen JC, Prasad V, Brenner W, Diederichs G, Hamm B, et al. Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with (68)Ga-PSMA-HBED-CC PET-positive prostate cancer lesions. EJNMMI Res. 2017;7(1):85.CrossRefPubMedPubMedCentral
35.
go back to reference Hofheinz F, Lougovski A, Zöphel K, Hentschel M, Steffen IG, Apostolova I, et al. Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2015;42(3):429–37.CrossRefPubMed Hofheinz F, Lougovski A, Zöphel K, Hentschel M, Steffen IG, Apostolova I, et al. Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2015;42(3):429–37.CrossRefPubMed
36.
go back to reference Rogasch JMM, Hundsdoerfer P, Furth C, Wedel F, Hofheinz F, Krüger PC, et al. Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on (123)I-MIBG SPECT predict the outcome? Eur J Nucl Med Mol Imaging. 2017;44(13):2203–12.CrossRefPubMed Rogasch JMM, Hundsdoerfer P, Furth C, Wedel F, Hofheinz F, Krüger PC, et al. Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on (123)I-MIBG SPECT predict the outcome? Eur J Nucl Med Mol Imaging. 2017;44(13):2203–12.CrossRefPubMed
37.
go back to reference Zschaeck S, Li Y, Lin Q, Beck M, Amthauer H, Bauersachs L, et al. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients. PLoS ONE. 2020;15(7):e0236841.CrossRefPubMedPubMedCentral Zschaeck S, Li Y, Lin Q, Beck M, Amthauer H, Bauersachs L, et al. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients. PLoS ONE. 2020;15(7):e0236841.CrossRefPubMedPubMedCentral
38.
go back to reference Mullikin JC, Verbeek PW. Surface area estimation of digitized planes. Bioimaging. 1993;1(1):6–16.CrossRef Mullikin JC, Verbeek PW. Surface area estimation of digitized planes. Bioimaging. 1993;1(1):6–16.CrossRef
39.
go back to reference Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69–71.PubMedPubMedCentral Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69–71.PubMedPubMedCentral
40.
go back to reference Rogasch JM, Suleiman S, Hofheinz F, Bluemel S, Lukas M, Amthauer H, et al. Reconstructed spatial resolution and contrast recovery with Bayesian penalized likelihood reconstruction (Q.Clear) for FDG-PET compared to time-of-flight (TOF) with point spread function (PSF). EJNMMI Phys. 2020;7(1):2.CrossRefPubMedPubMedCentral Rogasch JM, Suleiman S, Hofheinz F, Bluemel S, Lukas M, Amthauer H, et al. Reconstructed spatial resolution and contrast recovery with Bayesian penalized likelihood reconstruction (Q.Clear) for FDG-PET compared to time-of-flight (TOF) with point spread function (PSF). EJNMMI Phys. 2020;7(1):2.CrossRefPubMedPubMedCentral
41.
go back to reference Kaalep A, Burggraaff CN, Pieplenbosch S, Verwer EE, Sera T, Zijlstra J, et al. Quantitative implications of the updated EARL 2019 PET-CT performance standards. EJNMMI Phys. 2019;6(1):28.CrossRefPubMedPubMedCentral Kaalep A, Burggraaff CN, Pieplenbosch S, Verwer EE, Sera T, Zijlstra J, et al. Quantitative implications of the updated EARL 2019 PET-CT performance standards. EJNMMI Phys. 2019;6(1):28.CrossRefPubMedPubMedCentral
42.
go back to reference Tsutsui Y, Awamoto S, Himuro K, Umezu Y, Baba S, Sasaki M. Characteristics of smoothing filters to achieve the guideline recommended positron emission tomography image without harmonization. Asia Ocean J Nucl Med Biol. 2018;6(1):15–23.PubMedPubMedCentral Tsutsui Y, Awamoto S, Himuro K, Umezu Y, Baba S, Sasaki M. Characteristics of smoothing filters to achieve the guideline recommended positron emission tomography image without harmonization. Asia Ocean J Nucl Med Biol. 2018;6(1):15–23.PubMedPubMedCentral
43.
go back to reference Tsutsui Y, Daisaki H, Akamatsu G, Umeda T, Ogawa M, Kajiwara H, et al. Multicentre analysis of PET SUV using vendor-neutral software: the Japanese Harmonization Technology (J-Hart) study. EJNMMI Res. 2018;8(1):83.CrossRefPubMedPubMedCentral Tsutsui Y, Daisaki H, Akamatsu G, Umeda T, Ogawa M, Kajiwara H, et al. Multicentre analysis of PET SUV using vendor-neutral software: the Japanese Harmonization Technology (J-Hart) study. EJNMMI Res. 2018;8(1):83.CrossRefPubMedPubMedCentral
44.
go back to reference Kramer GM, Frings V, Hoetjes N, Hoekstra OS, Smit EF, de Langen AJ, et al. Repeatability of quantitative whole-body 18F-FDG PET/CT uptake measures as function of uptake interval and lesion selection in non-small cell lung cancer patients. J Nucl Med. 2016;57(9):1343–9.CrossRefPubMed Kramer GM, Frings V, Hoetjes N, Hoekstra OS, Smit EF, de Langen AJ, et al. Repeatability of quantitative whole-body 18F-FDG PET/CT uptake measures as function of uptake interval and lesion selection in non-small cell lung cancer patients. J Nucl Med. 2016;57(9):1343–9.CrossRefPubMed
Metadata
Title
Asphericity of tumor FDG uptake in non-small cell lung cancer: reproducibility and implications for harmonization in multicenter studies
Authors
Julian M. M. Rogasch
Christian Furth
Stephanie Bluemel
Piotr Radojewski
Holger Amthauer
Frank Hofheinz
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Keywords
NSCLC
NSCLC
Published in
EJNMMI Research / Issue 1/2020
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-020-00725-y

Other articles of this Issue 1/2020

EJNMMI Research 1/2020 Go to the issue